Engineering approaches for RNA-based and cell-based osteoarthritis therapies

Area of Science:

• Biomedical Engineering
• Molecular Biology
• Pharmacology

Background:

• Osteoarthritis (OA) is a chronic, debilitating condition with limited effective pharmacological treatments.
• Current OA therapies, like corticosteroids, offer only short-term palliation and do not halt disease progression.
• Understanding OA at molecular and cellular levels reveals diverse pathological drivers.

Purpose of the Study:

• To review emerging RNA-based and cell-based therapies for osteoarthritis.
• To highlight the potential of genetic medicines in transforming OA treatment paradigms.
• To present a framework for applying engineered therapies to target OA pathology.

Main Methods:

• Review of current literature on RNA-based technologies (siRNA, miRNA, mRNA, CRISPR-Cas9) for OA.
• Examination of cell-engineering strategies for therapeutic molecule delivery.
• Analysis of synthetic chemistry and biology tools in developing novel OA treatments.

Main Results:

• Engineered RNA and cell-based therapies show promise for durable and targeted OA treatment.
• Specific RNA technologies like small interfering RNA, microRNA, and mRNA offer distinct therapeutic mechanisms.
• CRISPR-Cas9 and advanced cell engineering enable precise, disease-dependent therapeutic interventions.

Conclusions:

• Modern genetic medicines, including RNA-based approaches, hold significant potential for osteoarthritis treatment.
• Cellular engineering strategies can enhance therapeutic efficacy and control.
• These advanced therapies could offer transformative, long-term solutions for osteoarthritis, moving beyond palliative care.